Borys W. Hrinczenko

Hematology

401 W Greenlawn Ave
Lansing, MI 48910

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 29 publications

Nitrous Oxide-Induced Pancytopenia and Peripheral Neuropathy From Chronic Whip-It™ Use: A Case Report.

Nitrous Oxide-Induced Pancytopenia and Peripheral Neuropathy From Chronic Whip-It™ Use: A Case Report.

Journal: Cureus

Published: July 17, 2026

Venous Thromboembolism Risk in Transgender Women on Feminizing Hormone Therapy: A Narrative Review of Formulation-Specific Risks, Management Strategies, and Evidence Gaps.

Venous Thromboembolism Risk in Transgender Women on Feminizing Hormone Therapy: A Narrative Review of Formulation-Specific Risks, Management Strategies, and Evidence Gaps.

Journal: Cureus

Published: June 18, 2026

Pernicious Anemia Presenting as Pseudo-Thrombotic Microangiopathy: A Case Report.

Pernicious Anemia Presenting as Pseudo-Thrombotic Microangiopathy: A Case Report.

Journal: Cureus

Published: May 26, 2026

Platypnea-Orthodeoxia Syndrome Presenting With Secondary Erythrocytosis.

Platypnea-Orthodeoxia Syndrome Presenting With Secondary Erythrocytosis.

Journal: Cureus

Published: May 17, 2026

CRE26-057: Rare Transformation of JAK2-Positive Primary Myelofibrosis to B-Cell Acute Lymphoblastic Leukemia: A Case Report and Molecular Analysis.

CRE26-057: Rare Transformation of JAK2-Positive Primary Myelofibrosis to B-Cell Acute Lymphoblastic Leukemia: A Case Report and Molecular Analysis.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 29, 2026

Nivolumab after recurrent pembrolizumab-associated hepatotoxicity in PD-L1-high metastatic squamous non-small cell lung cancer: a case report.

Nivolumab after recurrent pembrolizumab-associated hepatotoxicity in PD-L1-high metastatic squamous non-small cell lung cancer: a case report.

Journal: Oxford medical case reports

Published: April 28, 2026

HSR26-207: Real-World Survival and Toxicity Outcomes of Tarlatamab in Relapsed or Refractory Small-Cell Lung Cancer: A Multicenter TriNetX Analysis Across Academic and Non-Academic Centers.

HSR26-207: Real-World Survival and Toxicity Outcomes of Tarlatamab in Relapsed or Refractory Small-Cell Lung Cancer: A Multicenter TriNetX Analysis Across Academic and Non-Academic Centers.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 16, 2026

Hemorrhagic Ascites in Chronic Lymphocytic Leukemia With Immunoglobulin Heavy Chain Variable Region 3-21 (IGHV3-21) Usage: A Case Requiring Individualized Treatment.

Hemorrhagic Ascites in Chronic Lymphocytic Leukemia With Immunoglobulin Heavy Chain Variable Region 3-21 (IGHV3-21) Usage: A Case Requiring Individualized Treatment.

Journal: Cureus

Published: April 05, 2026

HSR26-207: Real-World Survival and Toxicity Outcomes of Tarlatamab in Relapsed or Refractory Small-Cell Lung Cancer: A Multicenter TriNetX Analysis Across Academic and Non-Academic Centers.

HSR26-207: Real-World Survival and Toxicity Outcomes of Tarlatamab in Relapsed or Refractory Small-Cell Lung Cancer: A Multicenter TriNetX Analysis Across Academic and Non-Academic Centers.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 31, 2026

CRE26-057: Rare Transformation of JAK2-Positive Primary Myelofibrosis to B-Cell Acute Lymphoblastic Leukemia: A Case Report and Molecular Analysis.

CRE26-057: Rare Transformation of JAK2-Positive Primary Myelofibrosis to B-Cell Acute Lymphoblastic Leukemia: A Case Report and Molecular Analysis.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 31, 2026

A Trend Analysis of Metastatic Lung Cancer Disparities in the United States in the Era of Lung Cancer Screening.

A Trend Analysis of Metastatic Lung Cancer Disparities in the United States in the Era of Lung Cancer Screening.

Journal: Cureus

Published: May 31, 2025

Randomized phase II study of consolidation immunotherapy with nivolumab and ipilimumab or nivolumab alone following concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small-cell lung cancer (NSCLC): Big Ten Cancer Research Consortium LUN16-081.

Randomized phase II study of consolidation immunotherapy with nivolumab and ipilimumab or nivolumab alone following concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small-cell lung cancer (NSCLC): Big Ten Cancer Research Consortium LUN16-081.

Journal: Journal for immunotherapy of cancer

Published: May 28, 2025

Showing 1-12 of 29

Last Updated: 09/26/2026